Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The POPADAD (Prevention Of Progression of Arterial Disease And Diabetes) study did not show a benefit for low-dose aspirin therapy or administration of antioxidants for the primary prevention of cardiovascular disease events in individuals with diabetes and asymptomatic peripheral arterial disease. Although low-dose aspirin continues to be recommended in international guidelines, no convincing trial-based evidence exists that supports its routine use for primary prevention of cardiovascular disease in people with diabetes. This paradox is unhelpful and the guidelines should be relaxed until definitive evidence becomes available.

Original publication

DOI

10.1038/ncpcardio1446

Type

Journal article

Journal

Nat Clin Pract Cardiovasc Med

Publication Date

03/2009

Volume

6

Pages

168 - 169

Keywords

Antioxidants, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Diabetic Angiopathies, Humans, Peripheral Vascular Diseases, Platelet Aggregation Inhibitors, Primary Prevention